Straits Times Index
3,090.20 -20.53 (-0.66%) S&P 500
4,603.91 -0.46 (-0.01%) Dow
36,331.98 +84.11 (+0.23%) Nasdaq
14,346.29 -57.69 (-0.40%) Bitcoin USD
41,477.09 -2,411.32 (-5.49%) CMC Crypto 200
856.68 -58.13 (-6.35%)
OSE Immunotherapeutics SA (0RAD.L)
| Previous close | 4.0250 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 8,806 |
| Market cap | 520,882 |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireOSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
NANTES, France, December 11, 2023--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210313768/en/
Business WireOSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®
NANTES, France, November 21, 2023--OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has entered into a collaboration with GenDx (a Eurobio Scientific Company, a key player in the field of specialty in vitro diagnostics) to develop and validate a companion diagnostic (CDx) test to support the confirmatory pivotal Phase 3 clinical trial of Tedopi® cancer vaccine candidate in preparation in Non-Small Cell Lung Cancer (NSCLC) second line treatment. GenDx, o
Business WireOSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
NANTES, France, October 23, 2023--OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
